A danazol-loaded intrauterine device decreases dysmenorrhea, pelvic pain, and dyspareunia associated with endometriosis.

Abstract

A danazol-loaded intrauterine device (IUD) containing 300-400 mg of danazol was inserted for 6 months in a group of women (n = 18) (median age 36.6 years; age range: 30 to 46 years) with a histologic diagnosis of endometriosis, referred for recurrent pelvic pain. Dysmenorrhea, dyspareunia, and pelvic pain significantly decreased after the first month, with a persistent effect during the 6 months of IUD insertion. These results show that a danazol-loaded IUD is an effective conservative therapy for patients with endometriosis-related pelvic pain.

• Authors: Luigi Cobellis, Sandro Razzi, Antonio Fava, Filiberto M Severi, Masao Igarashi, Felice Petraglia
• Journal: Fertility and sterility (Fertil Steril) Vol. 82 Issue 1 Pg. 239-40 (Jul 2004) ISSN: 0015-0282 [Print] United States
• PMID: 15237024 (Publication Type: Clinical Trial, Letter)

Chemical References

• Estrogen Antagonists
• Danazol

Topics

• Adult
• Danazol (administration & dosage)
• Dysmenorrhea (drug therapy, etiology)
• Dyspareunia (drug therapy, etiology)
• Endometriosis (complications)
• Estrogen Antagonists (administration & dosage)
• Female
• Humans
• Intrauterine Devices, Medicated
• Middle Aged
• Treatment Outcome